{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ10717",
      "entity_text" : "CD19 CAR",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q14116",
      "entity_text" : "IL-18",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "These results collectively demonstrate that IL-18 can significantly enhance TCR KO CD19 CAR T cell proliferation and induces superior antitumor activity without TCR mediated GVHD during therapy and that systemic IL-18 levels wane following elimination of the tumor burden.",
  "reading_complete" : "2020-08-08T13:54:20Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T13:52:03Z",
  "trigger" : "enhance",
  "evidence" : [ "IL-18 can significantly enhance TCR KO CD19 CAR" ],
  "pmc_id" : "6002762",
  "score" : 0
}